This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shamir, R Articles by Lerner, A Search for Related Content PubMed PubMed Citation Articles by Shamir, R Articles by Lerner, A Social Bookmarking                   What's this?

The prevalence of coeliac disease antibodies in patients with the antiphospholipid syndrome

Division of Paediatric Gastroenterology and Nutrition, Meyer Children’s Hospital of Haifa, Haifa, Israel, shamirr{at}netvision.net.il

Y Shoenfeld

Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Isreal

M Blank

Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Isreal

R Eliakim

Department of Gastroenterology, Rambam Medical Center, Haifa, Israel

N Lahat

Department of Immunology, Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

E Sobel

Department of Immunology, Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

E Shinar

MDA National Blood Services, Israel

A Lerner

Department of Paediatrics, Carmel Medical Center, Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

High prevalence of coeliac disease (CD) has been reported in various autoimmune disorders, but has not been studied in the antiphospholipidsyndrome (APS). We aimed to establishthe prevalenceof CD antibodiesin a cohort of APS patients, and to examine whether CD may be responsiblefor some of the manifestationsof APS. Fifty-seven patients (47 females, 10 males) with APS were studied for clinical manifestations and serological markers of the disease, as well as the presence of anti-endomysial antibodies using an ELISA assay (EMA-ELISA). Control subjects were 171 healthy individuals, ageand sex-matched (141 females). Eight patients with APS (14%, six females) were found to have EMA-ELISA antibodies, compared with 2/141 (1.1%) of controls (P 0.0003). Antibodies against b2-glycoprotein-I (b2GPI) epitopes (GRTCPKPDDLP) were more prevalent in EMA-positive patients than in EMA-negative patients (P 0.006). Vasculitic skin lesions were significantly more common in EMA-ELISA-positive compared with EMA-ELISA-negative patients (62.5 versus 16.3%, P 0.01). Among the skin manifestations, superficial cutaneous necrosis (37.5 versus 2%, P 0.007) was more prevalent in EMA-ELISA-positive than in EMA-ELISA-negative patients. EMA-ELISA antibodies are common in APS, and their presence is associated with high prevalence of antibodies recognizing certain b2-glycoprotein epitopes, and with cutaneous manifestations of APS.

Key Words: anti-b2-glycoprotein-I antibodies • anti-endomysial antibodies • antiphospholipid syndrome • autoimmunity • coeliac disease • tissue transglutaminase

Lupus, Vol. 12, No. 5, 394-399 (2003)
DOI: 10.1191/0961203303lu384oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P A Courtney, R N Patterson, R J. Lee, and S A McMillan Letter to the Editor Lupus, March 1, 2004; 13(3): 214 - 214. [PDF]